Related Experiment Video
Updated: May 28, 2026
A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
Comparison of methodologies for KRAS mutation detection in metastatic colorectal cancer
Pedro Pinto1, Patrícia Rocha, Isabel Veiga
1Department of Genetics, Portuguese Oncology Institute, Porto, Portugal.
Abstract:
Cetuximab and panitumumab are two monoclonal antibodies targeting the epidermal growth factor receptor that have been approved for treatment of metastatic colorectal cancer. Recent clinical trials found an association between KRAS mutation status and resistance to anti-epidermal growth factor receptor therapy, leading to the recommendation to perform KRAS mutation analysis before cetuximab or panitumumab treatment. This study was designed to compare and evaluate the efficacy of four different methodologies--high resolution melting, Sanger sequencing, DxS kit, and SNaPshot--for KRAS mutation detection in a clinical setting. In total, 372 samples from patients with metastatic colorectal cancer were analyzed by high resolution melting and SNaPshot, with 184 of those being further analyzed by Sanger sequencing and 188 with the DxS kit. Sensitivities were compared after consensus findings were determined by the presence of the same result in two of the three methodologies used in each case. The frequency of KRAS codon 12 and 13 mutations in our population was 43.5%, and a discordant finding was observed in 22 samples. Comparing to Sanger sequencing, significantly more consensus mutations were detected by the DxS kit (P=0.0139), high resolution melting (P=0.0004), and SNaPshot (P=0.00001), but no statistically significant differences were found among the three methodologies with higher sensitivity.
Insights
KRAS mutation testing is crucial for metastatic colorectal cancer patients receiving EGFR inhibitor therapy. This study found high-resolution melting, DxS kit, and SNaPshot methods are more sensitive than Sanger sequencing for detecting KRAS mutations.
Area of Science:
- Oncology
- Molecular Diagnostics
- Genetics
Background:
- Cetuximab and panitumumab target epidermal growth factor receptor (EGFR) for metastatic colorectal cancer (mCRC).
- KRAS mutation status influences patient response to anti-EGFR therapy, necessitating pre-treatment genetic analysis.
- Accurate KRAS mutation detection is critical for personalized mCRC treatment strategies.
Purpose of the Study:
- To compare the clinical efficacy of four KRAS mutation detection methods: high-resolution melting (HRM), Sanger sequencing, DxS kit, and SNaPshot.
- To evaluate the sensitivity and reliability of these methodologies in a real-world clinical setting for mCRC patients.
Main Methods:
- Analysis of 372 mCRC patient samples using HRM and SNaPshot.
- Further analysis of subsets using Sanger sequencing (184 samples) and DxS kit (188 samples).
- Consensus findings determined by agreement across at least two of three employed methodologies per sample.
Main Results:
- The overall frequency of KRAS codon 12 and 13 mutations was 43.5% in the study population.
- The DxS kit, HRM, and SNaPshot demonstrated significantly higher sensitivity for detecting consensus mutations compared to Sanger sequencing (P<0.0139).
- No statistically significant differences in sensitivity were observed among DxS kit, HRM, and SNaPshot.
Conclusions:
- The DxS kit, high-resolution melting, and SNaPshot are more sensitive KRAS mutation detection methods than Sanger sequencing for clinical use in mCRC.
- These findings support the use of more sensitive molecular diagnostic tools for guiding anti-EGFR therapy selection in colorectal cancer patients.
- Accurate KRAS mutation testing is essential for optimizing treatment outcomes in metastatic colorectal cancer.
